NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Best-Link Bioscience

Shanghai Best-Link Bioscience

Private
ShanghaiHealthcare & Life Scienceshttp://bestlinkbio.com/

Last Round

Series C

May 15, 2026

Total Funding Raised

$153.39M

Company Overview

Shanghai Best-Link Bioscience is a biotechnology company that develops innovative drugs for tumor therapy using its proprietary nano-conjugate drug platform (NMPDC®).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

nano-conjugate drugNMPDConcologytumor immunotherapyprecision drug deliverysolid tumor treatmentADCbiotechantibody-drug conjugatesdrug licensingclinical-stage biotechtargeted therapydrug pipelinenanomedicinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Best-Link Bioscience Comps

Public and private peers based on sector, stage, and business model.

Shanghai Best-Link Bioscience comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Shanghai Best-Link Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 15, 2026
Series BJan 28, 2026
Series BJan 28, 2024
Series AApr 8, 2023
AngelJun 10, 2021

Shanghai Best-Link Bioscience Investors

Notable investors and investment history

Shanghai Best-Link Bioscience investors
InvestorRounds
Tianjin TEDA Science and Technology Investment Co., Ltd.Series B
Lapam CapitalSeries B, Series A
Tigeryeah CapitalSeries B, Series A
Zhongke ChuangxingSeries B
Yonghua CapitalSeries B
Hyfinity InvestmentsSeries A

Shanghai Best-Link Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Best-Link Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Best-Link Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingMay 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.